Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma

Molecular Therapy

Volumn 8, Issue 4, 2003, Pages 552-558

  Kishida, Tsunao ^a   Asada, Hidetsugu ^a   Itokawa, Yoshiki ^a   Cui, Feng De ^a   Shin Ya, Masaharu ^a   Gojo, Satoshi ^b   Yasutomi, Kakei ^a   Ueda, Yuji ^a   Yamagishi, Hisakazu ^a   Imanishi, Jiro ^a   Mazda, Osam ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Gene therapy; Hydrodynamics; IL 15; IL 21; Malignancy; Naked DNA

Indexed keywords

CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 21; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER REGRESSION; CANCER TRANSPLANTATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; IN VIVO STUDY; INOCULATION; LIVER METASTASIS; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOMA CELL; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; SPLEEN; SURVIVAL TIME; T LYMPHOCYTE; TAIL; TUMOR IMMUNITY;

ANIMALIA;

EID: 10744230081     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00222-3     Document Type: Article

References (46)

1. Tagawa, M (2000). Cytokine therapy for cancer. Curr. Pharm. Des. 6: 681-699.
2. Mazda, O., and Germeraad, W. T. (2003). Tumor immunity and immuno-gene therapy of malignancies. In Frontiers in Immuno-gene Therapy (O. Mazda, Ed.). Research Sign-post, Trivandrum, India (in press).
3. Parrish-Novak, J, et al. (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63.
4. Parrish-Novak, J., Foster, D. C., Holly, R. D., and Clegg, C. H. (2002). Interleukin-21 and the IL-21 receptor: Novel effectors of NK and T cell responses. J. Leukocyte Biol. 72: 856-863.
5. Asao, H., et al. (2001). Cutting edge: The common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167: 1-5.
6. Habib, T., Senadheera, S., Weinberg, K., and Kaushansky, K. (2002). The common gamma chain (gamma C) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41: 8725-8731.
7. Kasaian, M. T., et al. (2002). IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569.
8. Strengell, M., Sareneva, T., Foster, D., Julkunen, I., and Matikainen, S. (2002). IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169: 3600-3605.
9. Suto, A., et al. (2002). Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 100: 4565-4573.
10. Ozaki, K., et al. (2002). A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630-1634.
11. Carson, W. E., et al. (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180: 1395-1403.
12. Ohteki, T. (2002). Critical role for IL-15 in innate immunity. Curr. Mol. Med. 2: 371-380.
13. Waldmann, T. A., and Tagaya, Y. (1999). The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17: 19-49.
14. Giri, J. G., et al. (1995). Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14: 3654-3663.
15. + hematopoietic progenitor cells. Blood 87: 2632-2640.
16. Carson, W. E., et al. (1997). A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99: 937-943.
17. Cooper, M. A., et al. (2002). In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638.
18. + T cells in vivo by IL-15. Immunity 8: 591-599.
19. Kennedy, M. K., et al. (2000). Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191: 771-780.
20. Wilkinson, P. C., and Liew, F. Y. (1995). Chemoattraction of human blood T lymphocytes by interleukin-15. J. Exp. Med. 181: 1255-1259.
21. Fehniger, T. A., et al. (2000). Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J. Immunol. 164: 1643-1647.
22. Liu, F., Song, Y., and Liu, D. (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266.
23. Zhang, G., Budker, V., and Wolff, J. A. (1999). High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10: 1735-1737.
24. Cui, F. D., et al. (2001). Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein-Barr virus (EBV)-based plasmid vectors. Gene Ther. 8: 1508-1513.
25. Wurster, A. L., et al. (2002). Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med. 196: 969-977.
26. Eberl, M., et al. (2002). Accumulation of a potent gammadelta T-cell stimulator after deletion of the lytB gene in Escherichia cali. Immunology 106: 200-211.
27. Brenne, A. T., et al. (2002). Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99: 3756-3762.
28. Di Carlo, E., et al. (2000). Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice. J. Pathol. 191: 193-201.
29. Suzuki, K., et al. (2001). NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukocyte Biol. 69: 531-537.
30. Sharif-Askari, E., Fawaz, L. M., Tran, P., Ahmad, A., and Menezes, J. (2001). Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J. Natl. Cancer Inst. 93: 1724-1732.
31. Colombo, M. P., and Trinchieri, G. (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 155-168.
32. Kishida, T., et al. (2001). In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 8: 1234-1240.
33. Asada, H., et al. (2002). Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin-12 (IL-12) and IL-18 by means of the EBV/lipoplex. Mol. Ther. 5: 609-616.
34. Motzer, R. J., et al. (1998). Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4: 1183-1191.
35. Chikano, S., et al. (2000). IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 47: 779-786.
36. Ugai, S., et al. (2003). Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 10: 187-192.
37. Lui, V. W., He, Y., Falo, L., and Huang, L. (2002). Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum. Gene Ther. 13: 177-185.
38. Itokawa, Y., et al. (2002). Hydrodynamics-based immuno-gene therapy against metastatic liver tumor and peritoneal carcinomatosis. Mol. Ther. 5: S101.
39. Eastman, S. J., et al, (2002). Development of catheter-based procedures for transclucing the isolated rabbit liver with plasmid DNA. Hum. Gene Ther. 13: 2065-2077.
40. Liu, F., and Huang, L. (2002). Noninvasive gene delivery to the liver by mechanical massage. Hepatology 35: 1314-1319.
41. Grabstein, K. H., et al. (1994). Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264: 965-968.
42. Nakanishi, H., et al. (2003). Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Ther. 10: 434-442.
43. Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
44. Yates, J. L., Warren, N., and Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815.
45. Mazda, O., Satoh, E., Yasutomi, K., and Imanishi, J. (1997). Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. J. Immunol. Methods 204: 143-151.
46. Osaki, T., et al. (1999). Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther. 6: 808-815.